Endometrial Carcinoma malady

Wikipedia: Endometrial cancer refers to several types of malignancies that arise from the endometrium, or lining,...⁴⁴ more...

MalaCards: Endometrial Carcinoma, also known as endometrioid carcinoma, is related to carcinoma and prostatitis. An important gene associated with Endometrial Carcinoma is P2RY2 (purinergic receptor P2Y, G-protein coupled, 2), and among its related pathways are Small cell lung cancer and Non-small cell lung cancer. The drugs carmustine and diethylstilbestrol diphosphate and the compounds progesterone and calcium have been mentioned in the context of this disorder. Affiliated tissues include the tissue lining the uterus, lymph node and colon, and related mouse phenotypes are growth/size and nervous system.

Disease Ontology: A endometrial cancer that is located in the tissue lining the uterus.⁶

Aliases & Descriptions:

endometrial carcinoma 6 7 8 33 32 43 endometrioid carcinoma 6 8 endometrioid carcinoma of female reproductive system 6 endometrioid carcinoma (morphologic abnormality) 6 endometrial carcinoma (disorder) 6

carcinoma of the endometrium 6 carcinoma of endometrium 6 carcinoma, endometrioid 43 carcinoma endometrioid 32 carcinoma 43

Diseases related to endometrial carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1609)

id	Related Disease	Score	Top Affiliating Genes
1	carcinoma	65.3	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, LRPAP1
2	prostatitis	55.9	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA1
3	breast carcinoma	55.4	PIK3CA, PIK3CG, LRP1, LRPAP1, NCOA3, NCOR1
4	hepatocellular carcinoma	54.3	PIK3CB, PIK3CA, PIK3CG, NCOA3, RELA, CNR2
5	thyroiditis	53.0	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, LRPAP1
6	pancreatitis	50.6	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA3
7	lung carcinoma	50.2	PIK3CA, PIK3CG, PCNA, RB1, SERPINB5, SERPINB2
8	melanoma	48.8	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA3
9	adenocarcinoma	48.6	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, KLF9
10	hepatitis	48.3	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA3
11	esophagitis	48.2	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, NCOA3, RELA
12	adenoma	47.1	PIK3CA, NCOA1, NCOA3, NCOR1, NCOR2, KIT
13	cervicitis	45.4	PIK3CA, PIK3CG, RELA, KIT, KIR2DL3, SFN
14	endometrial cancer	45.1	PIK3CB, PIK3CA, PIK3CG, NCOA1, NCOA3, KIAA1324
15	squamous cell carcinoma	45.0	RBP1, CD44, CDH1, MMP26, MMP7, MKI67
16	laryngitis	44.9	PIK3CA, RELA, SFN, PCNA, RB1, RBP1
17	leukemia	44.9	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, LRPAP1
18	neuronitis	44.5	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, LRPAP1
19	oral squamous cell carcinoma	44.5	PIK3CA, PIK3C2A, SFN, SFRP1, SFRP5, PCNA
20	gastric cancer	44.4	PIK3CB, PIK3CA, PIK3CG, NCOA3, RELA, KIT
21	colorectal cancer	43.5	PIK3CB, PIK3CA, PIK3CG, LRPAP1, KLF9, NCOA3
22	thyroid carcinoma	43.2	PIK3CA, PIK3CG, SFN, PCNA, RB1, SERPINB2
23	ovarian carcinoma	42.8	PIK3CA, PIK3CG, NCOA3, RELA, KIT, KISS1
24	esophageal squamous cell carcinoma	42.8	PIK3CA, NCOA3, RELA, KIT, KISS1, KISS1R
25	bladder carcinoma	42.8	PIK3CA, PIK3CG, SFN, PCNA, RB1, SERPINB5
26	endometrial adenocarcinoma	42.6	PIK3CA, KLF9, KIT, PCNA, RB1, RBP1
27	non-small cell lung carcinoma	41.7	PCNA, RB1, BRAF, VEGFA, VEGFC, MYC
28	laryngeal squamous cell carcinoma	41.4	SFN, PCNA, RB1, RBP1, BSG, VEGFA
29	squamous cell carcinoma of the head and neck	41.1	PIK3CA, PIK3CG, RB1, VEGFA, VEGFC, MYC
30	ductal carcinoma in situ	41.0	PIK3CA, KIT, PCNA, RB1, SERPINE1, VIM
31	nasopharyngitis	40.8	PIK3CA, PIK3CG, NCOA3, RELA, KIT, KIR2DL3
32	pancreatic carcinoma	40.7	PIK3CA, PCNA, RB1, SERPINB5, SERPINB2, VIM
33	prostate carcinoma	40.7	BRCA2, VEGFA, VDR, PARP1, CDH1, MMP9
34	laryngeal carcinoma	40.6	RELA, PCNA, RB1, SERPINB5, SERPINB2, BSG
35	papillary thyroid carcinoma	40.5	SERPINB5, BRAF, VEGFC, RARA, RARB, RASSF1
36	cholangiocarcinoma	40.3	PIK3CA, PIK3CG, KIT, KIAA1324, SFN, PCNA
37	adenoiditis	40.2	PIK3CA, RELA, KIT, SFN, PCNA, SERPINB5
38	sarcoma	39.9	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, NCOA1, NCOA3
39	basal cell carcinoma	39.7	VDR, RARA, BCL2, BAX, LAMC2, XRCC1
40	hypoxia	39.6	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA1
41	hepatitis b	39.3	PIK3CA, PIK3C2A, PIK3CG, RELA, KIR2DL3, PCNA
42	colon carcinoma	38.9	PIK3CB, PIK3CA, PIK3CG, KIT, SERPINB2, SERPINE1
43	small cell carcinoma	38.9	KIT, PCNA, RB1, VIM, BRCA1, BRCA2
44	endometriosis	38.8	PIK3CA, KLF9, NCOA1, NCOR1, NCOR2, RELA
45	colon cancer	37.9	PIK3CB, PIK3CA, PIK3CG, NCOR2, RELA, CNR2
46	clear cell renal cell carcinoma	37.7	RELA, KIT, SFRP1, SERPINE1, VIM, VHL
47	esophageal carcinoma	37.6	KIT, PCNA, RB1, SERPINB5, VEGFA, VEGFC
48	cervical cancer	37.4	PIK3CA, PIK3CG, RELA, SFN, SFRP1, PCNA
49	gallbladder carcinoma	37.1	PIK3CA, LRPAP1, PCNA, SERPINB5, VEGFA, VEGFC
50	cervical carcinoma	37.0	PIK3CA, PIK3CG, RELA, KIT, PCNA, RB1

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 carmustine, diethylstilbestrol, diethylstilbestrol diphosphate, nilutamide

MalaCards organs/tissues related to endometrial carcinoma:

²²

FMA organs/tissues related to endometrial carcinoma:

¹¹

MGI Mouse Phenotypes related to endometrial carcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size phenotype	MP:0005378	17.6	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, NCOA1
2	nervous system phenotype	MP:0003631	16.6	LRP1, LRPAP1, NCOA1, NCOR1, RELA, KIT
3	mortality/aging	MP:0010768	16.5	PIK3CB, PIK3CA, PIK3C2A, LRP1, LRPAP1, NCOR1
4	homeostasis/metabolism phenotype	MP:0005376	15.7	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, LRP1, LRPAP1
5	integument phenotype	MP:0010771	15.4	PIK3CG, NCOA1, NCOA3, NCOR1, RELA, CNR2
6	digestive/alimentary phenotype	MP:0005381	15.3	NCOA3, NCOR2, KIT, KISS1, KISS1R, SFN
7	cellular phenotype	MP:0005384	15.2	PIK3CB, PIK3CA, PIK3CG, NCOA3, NCOR1, NCOR2
8	embryogenesis phenotype	MP:0005380	15.2	PIK3CB, PIK3CA, NCOA1, NCOA3, NCOR1, KIT
9	immune system phenotype	MP:0005387	14.6	LRP1, NCOA1, NCOA3, NCOR1, CNR2, KIT
10	hematopoietic system phenotype	MP:0005397	14.3	KIT, KISS1R, SFN, SFRP1, PCNA, RBP1
11	skeleton phenotype	MP:0005390	14.1	PIK3CG, LRP1, NCOA1, RELA, KIT, SFN
12	renal/urinary system phenotype	MP:0005367	13.8	LRPAP1, NCOA1, NCOA3, KIT, KISS1, KISS1R
13	reproductive system phenotype	MP:0005389	13.8	PIK3CA, LRPAP1, NCOA1, NCOA3, KISS1, KISS1R
14	limbs/digits/tail phenotype	MP:0005371	13.3	RELA, KIT, SFN, SFRP1, SFRP5, RB1
15	endocrine/exocrine gland phenotype	MP:0005379	13.1	LRPAP1, NCOA1, KISS1, KISS1R, SFN, SFRP5
16	muscle phenotype	MP:0005369	13.0	PIK3CA, PIK3CG, LRP1, NCOA3, NCOR1, RELA
17	normal phenotype	MP:0002873	13.0	LRP1, LRPAP1, RELA, KISS1R, SFRP5, BRAF
18	cardiovascular system phenotype	MP:0005385	12.6	PIK3CB, PIK3CA, PIK3CG, LRP1, NCOR2, RELA
19	tumorigenesis	MP:0002006	12.6	PIK3CB, PIK3CA, NCOA3, KIT, SFN, RB1
20	no phenotypic analysis	MP:0003012	12.6	SFRP1, PCNA, RB1, VEGFA, VCAM1, LNPEP
21	behavior/neurological phenotype	MP:0005386	11.9	PIK3CA, LRP1, KLF9, NCOA1, NCOA3, NCOR1
22	craniofacial phenotype	MP:0005382	11.7	NCOA3, NCOR2, KIT, MYCN, BMI1, PAX8
23	vision/eye phenotype	MP:0005391	11.1	PIK3CA, RELA, KIT, SFN, RB1, RBP1
24	respiratory system phenotype	MP:0005388	10.9	BRCA1, MYCN, SCGB1A1, LEPR, FST, INSR
25	hearing/vestibular/ear phenotype	MP:0005377	10.6	NCOA3, KIT, SFN, RB1, RBP1, VDR
26	pigmentation phenotype	MP:0001186	10.5	KIT, RB1, RBP1, BRAF, BRCA1, MYC
27	adipose tissue phenotype	MP:0005375	10.0	PIK3CA, PIK3C2A, LRP1, NCOA3, NCOR1, NCOR2
28	liver/biliary system phenotype	MP:0005370	9.8	NCOA3, NCOR1, NCOR2, KIT, SFN, RBP1
29	other phenotype	MP:0005395	9.7	LRPAP1, RARA, RARB, CLU, KDR, LEPR

Articles related to endometrial carcinoma:

(show top 50)    (show all 717)

id	Title	Authors	Year	Affiliating Genes
1	Low-density lipoprotein receptor-related protein 1 (L RP-1) is associated with highgrade, advanced stage and p53 and p16 alterations in endometrial carcinomas. (22034896)	CatasA_s L.... Prat J.	2011	LRP1
2	Aberrant expression of the von Hippel-Lindau gene in human endometrial hyperplasia and endometrial carcinoma. (21436690)	Xu J.Y.... Wu J.	2011	VHL
3	Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro. (21442237)	Shu S.... Wang X.	2011	IGF1R
4	Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the prolifer ation of endometrial carcinoma cells. (20178884)	Fakhry H.... Shiozawa T.	2010	HDAC2, CDKN1A, CDKN2A
5	Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic signific ance. (20232213)	Toki N.... Kohno K.	2010	TFAM
6	Expression and activation of insulin receptor substrate-1 in endometrial carcinoma (19035139)	Hua S.F.... Zhao J.	2008	IRS1
7	Differential expression of clusterin according to histological type of endometrial carcinoma. (18514801)	Ahn H.J.... Sakuragi N.	2008	CLU
8	Effects of trichostatin A and paclitaxel on apoptosis and microtubule stabilization in endometrial carcinoma cells: an in vitro research (19087722)	Jiang S.J.... Wang Y.	2008	PARP1, ANXA5, CASP9
9	The development of papillary serous carcinoma of the peritoneum subsequent to endometrial carcinoma: a case report and review of the literature. (17986245)	Savas B.... Tezcan S.	2008	CALB2, CHKA
10	Induction of p16INK4A mediated by beta-catenin in a TCF4-independent manner: implications for alterations in p16INK4A and pRb expression during trans-differentiation of endometrial carcinoma cells. (16858682)	Saegusa M.... Okayasu I.	2006	CTNNB1, CDKN2A
11	Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA. (16550965)	Kawaguchi M.... Kuramoto H.	2006	CDKN1A, IFI27
12	Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. (16323174)	Broaddus R.R.... Lu K.H.	2006	MSH2
13	RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. (16619251)	Kang S.... Dong S.M.	2006	BRAF, KRAS, RASSF1
14	Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. (16677592)	Engelsen I.B.... Salvesen H.B.	2006	TP53, CDKN2A
15	Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. (15272278)	Chitale D.A.... Soslow R.A.	2005	TP53, MAGEA4
16	Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. (15720416)	Li S.S.... Cheung A.N.	2005	MCM7
17	Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. (15726651)	Pijnenborg J.M.... Kieback D.G.	2005	PGR
18	Defective mismatch repair and the development of recurrent endometrial carcinoma. (15297202)	Pijnenborg J.M.... Groothuis P.G.	2004	MLH1
19	Inhibition of the O-glycan elongation limits MUC1 incorporation to cell membrane of human endometrial carcinoma cells. (14767580)	Porowska H.... Gindzienski A.	2004	MUC1
20	Association between the expression of estrogen receptor subunit in endometrial carcinoma and the prognostic factors of endometrial carcinoma (15573770)	Zhang J.W.... Peng Z.L.	2004	ESR1, ESR2
21	Expression of cold-inducible RNA-binding protein in the normal endometrium, endometrial hyperplasia, and endometrial carcinoma. (12819390)	Hamid A.A.... Fujii S.	2003	CIRBP
22	Antisense oligodeoxynucleotides of human telomerase reverse transcriptase inhibit endometrial carcinoma cell HEC-1A proliferation (12839678)	Chen X.J.... Wang S.Q.	2003	TERT
23	Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. (12115348)	Baldinu P.... Palmieri G.	2002	MLH1
24	CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. (11957146)	Machin P.... Prat J.	2002	CTNNB1
25	Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. (11854177)	Zhou X.P.... Eng C.	2002	PTEN
26	Study of the mutation and expression of PTEN gene in endometrial carcinoma and epithelial ovarian cancer (12487936)	Che Y.... Wang Y.	2002	PTEN
27	Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. (11407475)	Sivridis E.... Anastasiadis P.	2001	BCL2, ESR1
28	Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. (11407474)	Palacios J.... Gamallo C.	2001	JUP, HNF4A
29	The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. (11571732)	Yaron M.... Friedman E.	2001	AR
30	PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. (11389092)	Zhu X.... Baker S.J.	2001	PTEN, CCND3, CDKN3
31	Amplification of Mycn, Ddx1, Rrm2, and Odc1 in rat uterine endometrial carcinomas. (11433525)	Karlsson A .... Levan G.	2001	MYCN
32	The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. (10682682)	Tsuda H.... Umesaki N.	2000	CDK4, CDK6, CDKN2A
33	Changes in connexin 43 protein expression in human endometrial carcinoma. (10600398)	Schlemmer S.R.... Kaufman D.G.	1999	GJA1
34	p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. (10101596)	Niwa K.... Tamaya T.	1999	TP53, PGR, ESR1
35	A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. (10451700)	Koul A.... Borg A.	1999	BRCA1, BRCA2
36	Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. (9596268)	Coppola D.... Jones M.	1998	TP53, BCL2, VIM
37	Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. (9648591)	Fukuda K.... Sugimori H.	1998	PGR, ESR1
38	Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. (9690546)	Pizer E.S.... Kurman R.J.	1998	FASN, PGR, ESR1
39	Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. (9852400)	Hata H.... Kuramoto H.	1998	PGR, TGFA
40	Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. (9306964)	Saegusa M.... Okayasu I.	1997	BCL2
41	Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. (8751548)	Hamel N.W.... Podratz K.C.	1996	TP53, PCNA
42	Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. (9037942)	Yabushita H.... Nakanishi M.	1996	VDR
43	Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor messenger RNA in human endometrium and endometrial carcinoma (7775814)	Sato A.... Mochizuki M.	1995	EGF, TGFA
44	Abnormal E-cadherin expression as a risk factor for deep myometrial invasion and lymph node metastasis in endometrial carcinoma (7629996)	Nomura E.... Fujimoto S.	1995	CDH1
45	Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. (7635451)	Niikura H.... Yajima A.	1995	EGFR
46	Development of a preclinical model for hormonal therapy of human endometrial carcinomas. (8489746)	Satyaswaroop P.G.	1993	PGR
47	Progesterone receptor content in endometrial carcinoma correlates with serum levels of free estradiol. (8213106)	Nyholm H.C.... Thorpe S.M.	1993	PGR
48	Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. (1442987)	Nyholm H.C.... Thorpe S.M.	1992	PGR
49	Designing a schedule of progestin administration in t he control of endometrial carcinoma growth in the nude mouse model. (2327463)	Mortel R.... Satyaswaroop P.G.	1990	PGR
50	The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. (2145248)	Kacinski B.M.... Ariza A.	1990	CSF1

Genes related to endometrial carcinoma according to GeneCards:

(show top 50)    (show all 443)

id	Symbol	Description	Score	GeneCards Section Context
1	P2RY2	purinergic receptor P2Y, G-protein coupled, 2	11.0	Summaries
2	PTEN	phosphatase and tensin homolog	11.0	Publications
3	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0	Publications
4	ESR1	estrogen receptor 1	11.0	Publications
5	TDGF1P3	teratocarcinoma-derived growth factor 1 pseudogene 3	11.0	Publications
6	ESRRA	estrogen-related receptor alpha	11.0	Publications
7	PGR	progesterone receptor	11.0	Publications
8	MMP26	matrix metallopeptidase 26	11.0	Publications
9	KLK4	kallikrein-related peptidase 4	11.0	Publications
10	CEACAM4	carcinoembryonic antigen-related cell adhesion molecule 4	11.0
11	UCN	urocortin	11.0	Publications
12	TRO	trophinin	11.0
13	HPR	haptoglobin-related protein	11.0	Publications
14	TFAP2C	transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)	11.0
15	HSD17B13	hydroxysteroid (17-beta) dehydrogenase 13	11.0	Publications
16	DPP3	dipeptidyl-peptidase 3	11.0	Publications
17	HOXA10	homeobox A10	11.0	Publications
18	KLF9	Kruppel-like factor 9	11.0	Publications
19	MLH1	mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)	11.0	Publications
20	LAP3	leucine aminopeptidase 3	11.0	Publications
21	GNRHR	gonadotropin-releasing hormone receptor	11.0	Publications
22	S100A6	S100 calcium binding protein A6	11.0	Publications
23	STOML2	stomatin (EPB72)-like 2	11.0
24	CLDN3	claudin 3	11.0
25	ERAP1	endoplasmic reticulum aminopeptidase 1	11.0	Publications
26	CEACAM1	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)	11.0	Publications
27	SULT1E1	sulfotransferase family 1E, estrogen-preferring, member 1	11.0	Publications
28	HSPA14	heat shock 70kDa protein 14	11.0	Publications
29	EBAG9	estrogen receptor binding site associated, antigen, 9	11.0
30	FGF3	fibroblast growth factor 3	11.0
31	DUSP13	dual specificity phosphatase 13	11.0
32	MUC16	mucin 16, cell surface associated	11.0	Publications
33	INHA	inhibin, alpha	11.0	Publications
34	ID1	inhibitor of DNA binding 1, dominant negative helix-loop-helix protein	11.0	Publications
35	TERC	telomerase RNA component	11.0	Publications
36	IFI27	interferon, alpha-inducible protein 27	11.0	Publications
37	CTNNB1	catenin (cadherin-associated protein), beta 1, 88kDa	11.0	Publications
38	SERPINB2	serpin peptidase inhibitor, clade B (ovalbumin), member 2	11.0	Publications
39	EFNB2	ephrin-B2	11.0	Publications
40	SKP2	S-phase kinase-associated protein 2, E3 ubiquitin protein ligase	11.0	Publications
41	LNPEP	leucyl/cystinyl aminopeptidase	11.0	Publications
42	FIGF	c-fos induced growth factor (vascular endothelial growth factor D)	11.0	Publications
43	ANG	angiogenin, ribonuclease, RNase A family, 5	11.0	Publications
44	APOD	apolipoprotein D	11.0	Publications
45	ARSH	arylsulfatase family, member H	11.0	Publications
46	TGFB3	transforming growth factor, beta 3	11.0	Publications
47	FGF7	fibroblast growth factor 7	11.0	Publications
48	CA9	carbonic anhydrase IX	11.0	Publications
49	EPHB4	EPH receptor B4	11.0	Publications
50	TP53	tumor protein p53	11.0	Publications, Functions

Pathways related to endometrial carcinoma according to GeneDecks:

(show top 50)    (show all 291)

id	Pathway	Score	Top Affiliating Genes
1	Small cell lung cancer20	12.6	PIK3CB, PIK3CA, PIK3CG, RELA, RB1, MYC
2	Non-small cell lung cancer20	12.4	PIK3CB, PIK3CA, PIK3CG, RB1, BRAF, RASSF1
3	Breast Cancer Regulation by Stathmin136	12.2	FIGF, FGF10, FGF2, FGF7, FGFR2, FGFR3
4	Pancreatic Adenocarcinoma36	12.2	KIT, RB1, BRAF, BRCA2, VEGFC, BIRC5
5	Cell cycle ESR1 regulation of G1/S transition10	12.0	NCOA3, RB1, MYC, CKS1B, JUN, CDK6
6	Cell cycle_ESR1 regulation of G1/S transition41	12.0	NCOA3, RB1, MYC, CKS1B, JUN, CDK6
7	Signal transduction_AKT signaling41	11.8	PIK3CB, PIK3CA, RELA, PCNA, MYC, BAX
8	Cyclins and Cell Cycle Regulation36	11.8	RB1, CDK6, CDKN1A, CDK2, CDKN1B, CDKN2A
9	Glioma Invasiveness36	11.8	VEGFC, CD44, FIGF, FGF10, FGF2, FGF7
10	Development_EGFR signaling pathway41	11.7	PIK3CB, PIK3CA, MYC, JUN, MMP2, MMP9
11	Glioblastoma Multiforme36	11.6	RB1, BRAF, CDK6, CDKN1A, CDK2, CDKN1B
12	Paxillin Interactions36	11.6	KIT, VEGFC, KDR, FLT1, FLT4, FIGF
13	PTEN Pathway36	11.6	KIT, BRAF, VEGFC, KDR, LAMC2, FLT1
14	ErbB signaling pathway20	11.6	PIK3CB, PIK3CA, PIK3CG, BRAF, MYC, MTOR
15	TGF-beta Signaling Pathways37	11.6	PIK3CB, PIK3CG, NCOR1, NCOR2, RELA, BRAF
16	Rho Family GTPases36	11.5	KIT, VIM, VEGFC, KDR, BCL2, BAX
17	p53 Signaling36	11.5	SFN, BRCA1, BCL2, BAX, CDKN1A, CDK4
18	14-3-3 Induced Intracellular Signaling36	11.5	VEGFC, JUN, FLT1, FLT4, FIGF, INSR
19	Development Thrombopoietin-regulated cell processes10	11.3	PIK3CB, PIK3CA, BRAF, MYC, BIRC5, JUN
20	Development_Thrombopoietin-regulated cell processes41	11.3	PIK3CB, PIK3CA, BRAF, MYC, BIRC5, JUN
21	Telomerase Components in Cell Signaling36	11.3	KIT, RB1, VEGFC, MYC, KDR, FLT1
22	Cell cycle Regulation of G1/S transition (part 2)10	11.2	RELA, RB1, JUN, CDK6, CDK2, CDK7
23	Cell cycle_Regulation of G1/S transition (part 1)41	11.2	BRCA1, CDK6, CDKN1A, CDK2, CDKN1B, CDKN2A
24	EGFR Inhibitor Pathway, Pharmacodynamics34	11.0	CAMK1, HRAS, KRAS
25	Sorafenib Pharmacodynamics34	11.0	PIK3CA, PIK3C2A, BRAF, KDR, FLT1, FLT4
26	Development EGFR signaling pathway10	11.0	NFKBIE
27	Development IGF-RI signaling10	10.9	PIK3CB, PIK3CA, RELA, MYC, MTOR, IRS1
28	Development_IGF-1 receptor signaling41	10.9	PIK3CB, PIK3CA, RELA, MYC, MTOR, IRS1
29	Adherens junction20	10.9	CDH1, INSR, MET, MAPK3, MAPK1, IGF1R
30	Cellular Apoptosis Pathway36	10.8	KIT, VEGFC, KDR, BCL2, BAX, CFLAR
31	Activation of cAMP-Dependent PKA36	10.8	VEGFC, KDR, UCN, FLT1, FLT4, FIGF
32	Signal transduction AKT signaling10	10.8	PIK3CB, IRS1, GSK3B, NFKBIB, NFKBIE
33	Measles20	10.6	PIK3CB, PIK3CA, PIK3CG, RELA, CDK6, CDK2
34	GPCR Pathway36	10.6	KIT, BRAF, VEGFC, KDR, JUN, FOS
35	Apoptotic Pathways in Synovial Fibroblasts36	10.6	KIT, VEGFC, KDR, CFLAR, FLT1, FLT4
36	p53 Mediated Apoptosis36	10.6	KIT, VEGFC, KDR, BCL2, BAX, FLT1
37	Nanog in Mammalian ESC Pluripotency36	10.6	KIT, BRAF, VEGFC, KDR, FLT1, FLT4
38	GSK3 Signaling36	10.5	KIT, VEGFC, KDR, CDH2, CDH3, CDH13
39	Activation of PKC through GPCR36	10.5	KIT, VEGFC, KDR, FLT1, FLT4, FIGF
40	Activation of PKA through GPCR36	10.4	KIT, BRAF, VEGFC, KDR, UCN, FLT1
41	PPAR Pathway36	10.3	NCOA1, KIT, VEGFC, FLT1, FLT4, FIGF
42	Development VEGF signaling and activation10	10.3	PIK3CB, PIK3CA, RELA, VCAM1, KDR, JUN
43	PEDF Induced Signaling36	10.2	RELA, BRAF, BCL2, BAX, CFLAR, FOS
44	Transcription Androgen Receptor nuclear signaling10	10.2	NCOA1, NCOR1, CDKN1A, MMP2, AR, GSK3B
45	Transcription Receptor-mediated HIF regulation10	10.2	IRS1, INSR, MAPK3, MAPK1, IGF1R, IGFBP3
46	Phospholipase-C Pathway36	10.1	KIT, VEGFC, KDR, LAMC2, FLT1, FLT4
47	p70S6K Signaling36	10.1	KIT, VEGFC, KDR, IRS1, FLT1, FLT4
48	cAMP Pathway36	9.9	KIT, BRAF, VEGFC, KDR, UCN, FLT1
49	Influenza A20	9.7	PIK3CB, PIK3CA, PIK3CG, RELA, JUN, GSK3B
50	Chagas disease (American trypanosomiasis)20	9.3	PIK3CB, PIK3CA, PIK3CG, RELA, SERPINE1, CFLAR

Compounds related to endometrial carcinoma according to GeneDecks:

(show top 50)    (show all 455)

id	Compound	Score	Top Affiliating Genes
1	progesterone32 42 9 18 9	24.3	PIK3CA, KLF9, NCOA1, NCOA3, NCOR1, NCOR2
2	calcium32 9 18 9	20.8	PIK3C2A, LRP1, LRPAP1, RELA, KIT, KISS1
3	cysteine32	15.4	LRP1, PCNA, BRCA1, VDR, MYB, RARA
4	12-o-tetradecanoylphorbol 13-acetate32	15.3	RB1, SERPINB2, BRAF, MYC, RARA, RARB
5	doxorubicin32 34 9 9	17.4	PIK3CA, PIK3C2A, PIK3CG, KIT, VIM, BRCA1
6	adenylate32	14.1	PIK3CA, PIK3CG, CNR2, SERPINE1, VIM, VIPR1
7	glucose32	14.0	KIT, KISS1, VIPR1, BRAF, VHL, VEGFC
8	retinoid32	13.7	NCOA1, NCOA3, NCOR1, NCOR2, RBP1, VIM
9	cisplatin32 34 9 9	16.6	PIK3CA, PIK3C2A, CNR2, PCNA, RB1, SERPINB5
10	atp32	13.6	PIK3CB, PIK3CA, PIK3C2A, KIT, RB1, BRAF
11	fatty acid32	13.5	PIK3C2A, LRP1, NCOA1, SFN, RBP1, BRAF
12	threonine32	12.5	PAX8, MUC2, MUC5AC, AURKB, MSH6, CDK6
13	o6-methylguanine32	12.3	PCNA, BRAF, BRCA2, RARB, RASSF1, MSH2
14	creatinine32	12.3	PCNA, VDR, SCGB1A1, CHKA, CHGA, MUC1
15	formaldehyde32 18	13.3	KIT, PCNA, RB1, VIM, CHGA, MUC1
16	agarose32	12.2	KIT, BRCA1, MYC, MYCN, CLU, PARP1
17	chloramphenicol32 9 9	14.2	KLF9, SERPINE1, VIM, VDR, MYC, MYCN
18	hematoxylin32	12.0	KIT, PCNA, VIM, CHKA, CHGA, MUC1
19	camptothecin32 42 9 9	14.8	PIK3CG, PCNA, RB1, BRCA1, BRCA2, MYC
20	b 72332	11.7	PCNA, VIM, CHKA, CHGA, MUC1, MUC16
21	histamine32 18	12.6	PIK3CA, KIT, PCNA, VIM, VCAM1, CHGA
22	gf 109203x32 42	12.5	PIK3CB, PIK3CG, VEGFA, JUN, CDKN1A, CDKN3
23	batimastat32 42 9 9	14.5	MMP1, MMP14, MMP2, MMP26, MMP7, MMP8
24	eb 108932	11.5	PCNA, VDR, CLU, PARP1, BCL2, BAX
25	ionomycin32	11.4	PIK3CB, P2RY2, CDK6, CDK4, CD40, FOS
26	irinotecan32 34 9 9	14.4	KIT, BRAF, VEGFA, PARP1, BAX, XRCC1
27	celecoxib32 42 34 9 18 9	16.3	PIK3CG, PCNA, VEGFA, BIRC5, PARP1, KDR
28	gefitinib32 34 9 9	14.1	PIK3CA, PIK3CG, KIT, VIM, VEGFA, BIRC5
29	cetuximab32 34 9 9	14.1	BRAF, KDR, CDKN1B, CDKN3, IGF1R, ERBB2
30	phenylalanine32	11.1	MME, INSR, FGFR3, HPR, KRT5, CSF1
31	roscovitine32	11.1	PIK3CG, PCNA, VIM, BIRC5, PARP1, XIAP
32	valproic acid32 34 9 18 9	15.0	MYCN, CFLAR, CDK4, GSK3B, CYP1A1, CYP1B1
33	cyclophosphamide32 34 9 9	14.0	LTF
34	ns 39832 42	11.9	PIK3CG, PCNA, PARP1, CDKN1B, MMP1, FGF2
35	noxa32	10.6	BIRC5, BCL2, BAX, XIAP, CFLAR, CDKN1A
36	nmda32 42	11.6	PIK3CA, LRP1, KISS1R, VIM, XIAP, CDH2
37	betacarotene32	10.6	PCNA, RB1, RBP1, VDR, RARA, RARB
38	cholesterol32 9 18 9	13.6	PIK3CB, PIK3CA, PIK3C2A, LRP1, LRPAP1, NCOA1
39	pioglitazone32 9 9	12.5	NCOA1, NCOR2, BSG, VEGFA, VCAM1, RARA
40	mannitol32 9 9	12.5	VCAM1, S100B, CDKN3, CDH1, IRS1, FGF2
41	mitomycin c32	10.4	PCNA, RB1, BRCA1, BRCA2, VCAM1, BIRC5
42	acth32	10.3	PIK3C2A, LNPEP, LEPR, MUC1, UCN, CGB5
43	4-hydroxynonenal32 18	11.3	MYC, MYB, PARP1, CHKA, BAX, JUN
44	tacrolimus32 34 9 9	13.2	PIK3CA, PCNA, SERPINE1, VDR, MYC, MTOR
45	troglitazone32 42 9 9	13.0	PIK3CG, RB1, SERPINE1, VDR, VCAM1, RARA
46	sb 20358032 42	10.9	RB1, VIM, BSG, BRAF, VEGFA, VDR
47	indomethacin32 9 9	11.8	NCOA1, PCNA, VIM, MYC, BIRC5, KDR
48	prostacyclin32	9.7	PIK3C2A, SERPINE1, VEGFA, VCAM1, KDR, MME
49	curcumin32	9.4	PIK3CG, VEGFA, VCAM1, MYC, BIRC5, PARP1
50	losartan32 34 9 9	11.1	PCNA, SERPINE1, VCAM1, MMP1, FOS, IRS1

Cellular components related to endometrial carcinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:005634	16.9	PIK3CB, PIK3C2A, LRP1, KLF9, NCOA3, NCOR1
2	cytoplasm	GO:005737	15.5	PIK3C2A, PIK3CG, LRP1, NCOA3, RELA, KIT
3	plasma membrane	GO:005886	14.4	PIK3C2A, PIK3CG, LRPAP1, CNR2, KIT, KIR2DL3
4	nucleoplasm	GO:005654	13.2	NCOA1, NCOA3, NCOR1, NCOR2, RELA, PCNA
5	cytosol	GO:005829	12.9	PIK3CB, PIK3CA, PIK3C2A, PIK3CG, RELA, SFRP1
6	integral to plasma membrane	GO:005887	12.8	LRP1, CNR2, KIR2DL3, KIAA1324, VIPR1, LNPEP
7	extracellular region	GO:005576	12.6	LRPAP1, KISS1, SERPINB2, SERPINE1, VEGFA, VEGFC
8	perinuclear region of cytoplasm	GO:048471	12.1	LNPEP, LIMS1, CLU, BCL3, MT1E, LAMC2
9	nucleolus	GO:005730	12.1	NCOA3, NCOR2, PCNA, VIPR1, NACC1, BRCA2
10	cell surface	GO:009986	12.0	LRPAP1, KISS1R, SFRP1, VEGFA, VCAM1, RARA
11	transcription factor complex	GO:005667	11.3	RELA, PARP1, JUN, CDK2, CDK4, ETS1
12	cyclin-dependent protein kinase holoenzyme complex	GO:000307	11.2	CDK6, CDKN1A, CDK2, CDK4, CCNE1, CCND2
13	platelet alpha granule lumen	GO:031093	10.2	SERPINE1, VEGFA, VEGFC, CLU, FIGF, IGF1
14	caveola	GO:005901	9.8	CDH13, IRS1, INSR, FASLG, MAPK3, MAPK1
15	extracellular space	GO:005615	9.7	KIT, SFN, SFRP1, SFRP5, SERPINB5, SERPINB2

Biological processes related to endometrial carcinoma according to GeneDecks:

(show top 50)    (show all 84)

id	Name	GO ID	Score	Top Affiliating Genes
1	angiogenesis	GO:001525	12.7	PIK3CA, PIK3CG, SERPINE1, VEGFA, VEGFC, KDR
2	G1/S transition of mitotic cell cycle	GO:000082	12.6	PCNA, RB1, BCL2, CKS1B, CDK6, CDKN1A
3	cell cycle arrest	GO:007050	12.2	RB1, MYC, RASSF1, MSH2, CDK6, CDKN1A
4	signal transduction	GO:007165	12.2	PIK3CB, KIT, SFN, SFRP5, VEGFC, VDR
5	negative regulation of transcription from RNA polymerase II promoter	GO:000122	12.0	NCOR1, NCOR2, VHL, VDR, MYC, MYB
6	cell proliferation	GO:008283	11.7	SFN, PCNA, BOK, BHLHE41, CKS1B, S100B
7	female pregnancy	GO:007565	11.7	LNPEP, BCL2, SCGB1A1, UCN, IRF1, FLT1
8	apoptotic process	GO:006915	11.7	SFN, SFRP5, VIM, BRCA1, BOK, BIRC5
9	negative regulation of cell growth	GO:030308	11.6	SFRP1, RB1, BCL2, CDKN1A, CDKN1B, CDKN2A
10	epidermal growth factor receptor signaling pathway	GO:007173	11.5	PIK3CA, PIK3C2A, MTOR, CDKN1B, CDK1, FOXO1
11	transcription initiation from RNA polymerase II promoter	GO:006367	11.5	NCOR1, NCOR2, SERPINE1, VDR, MYC, RARA
12	induction of apoptosis by intracellular signals	GO:008629	11.5	MYC, CLU, BCL2, BAX, XIAP, MSH6
13	fibroblast growth factor receptor signaling pathway	GO:008543	11.4	PIK3CA, BRAF, MTOR, CDKN1B, CDK1, FOXO1
14	positive regulation of protein phosphorylation	GO:001934	11.4	VEGFA, MTOR, CD40, FLT4, INSR, ENG
15	response to estradiol stimulus	GO:032355	11.4	NCOA1, BRCA2, VDR, RARA, UCN, AURKA
16	positive regulation of epithelial cell proliferation	GO:050679	11.3	SFRP1, VEGFC, MYC, FGF10, FGF7, FGF9
17	blood coagulation	GO:007596	11.3	PIK3CB, PIK3CA, PIK3CG, SERPINB2, SERPINE1, BSG
18	negative regulation of apoptotic process	GO:043066	11.3	PIK3CG, RELA, SFRP1, SERPINE1, BRAF, VEGFA
19	positive regulation of apoptotic process	GO:043065	11.2	NCOA1, SFRP1, RARB, CLU, BAX, MMP9
20	response to organic cyclic compound	GO:014070	11.2	SFRP1, MSH2, JUN, CDKN1A, CDK1, FGF10
21	protein autophosphorylation	GO:046777	11.2	KIT, KDR, MTOR, AURKA, AURKB, FLT1
22	transforming growth factor beta receptor signaling pathway	GO:007179	11.2	NCOR1, NCOR2, SERPINE1, MYC, PARP1, JUN
23	response to peptide hormone stimulus	GO:043434	11.1	BSG, BRAF, IRS1, FAS, ANXA1, GJA1
24	insulin receptor signaling pathway	GO:008286	11.1	PIK3CB, PIK3CA, PIK3C2A, MTOR, CDK1, FOXO1
25	response to estrogen stimulus	GO:043627	11.0	SERPINE1, BRCA1, BCL2, CD24, FAS, ANGPT1
26	positive regulation of gene expression	GO:010628	11.0	NCOA3, KIT, BRAF, VEGFA, VDR, CD34
27	response to hypoxia	GO:001666	11.0	VEGFA, VCAM1, CLDN3, BCL2, XRCC1, CD24
28	induction of apoptosis	GO:006917	11.0	NACC1, BOK, BAX, CDKN1B, CDKN2A, IRF1
29	phosphatidylinositol-mediated signaling	GO:048015	10.9	PIK3CB, PIK3CA, PIK3C2A, PCNA, MTOR, AURKA
30	regulation of cell proliferation	GO:042127	10.9	KIT, SERPINE1, BRCA1, XIAP, MMP7, INHA
31	cellular response to interleukin-1	GO:071347	10.8	RELA, SFRP1, P2RY2, MMP9, IRF1, IL8
32	response to drug	GO:042493	10.8	SFRP1, VEGFC, MYC, BCL2, XRCC1, MSH2
33	negative regulation of cell proliferation	GO:008285	10.7	KISS1R, SFN, SFRP1, SFRP5, VHL, VDR
34	positive regulation of transcription from RNA polymerase II promoter	GO:045944	10.7	NCOA1, NCOA3, RELA, RB1, SERPINE1, BRCA1
35	virus-host interaction	GO:019048	10.7	RELA, RB1, VIM, VCAM1, KDR, BAX
36	positive regulation of transcription, DNA-dependent	GO:045893	10.7	NCOA1, NCOA3, RELA, SFRP1, RB1, BRCA1
37	positive regulation of angiogenesis	GO:045766	10.6	SERPINE1, VEGFA, KDR, CD34, MMP9, FLT1
38	positive regulation of cell migration	GO:030335	10.6	VEGFA, KDR, CDH13, MMP14, IRS1, FLT1
39	organ morphogenesis	GO:009887	10.5	BRAF, VEGFC, VDR, BHLHE41, BCL2, CDX2
40	positive regulation of ERK1 and ERK2 cascade	GO:070374	10.5	BRAF, KDR, CD44, FLT4, FGF10, FGF2
41	nerve growth factor receptor signaling pathway	GO:048011	10.4	PIK3CB, PIK3CA, RELA, BRAF, MTOR, CDKN1B
42	negative regulation of transcription, DNA-dependent	GO:045892	10.4	RELA, SFRP1, RB1, NACC1, BRCA1, VDR
43	positive regulation of peptidyl-serine phosphorylation	GO:033138	10.3	PIK3CA, BRAF, VEGFA, BCL2, CD44, GSK3B
44	positive regulation of cell proliferation	GO:008284	10.3	KIT, SFRP1, VIPR1, NACC1, VEGFA, VEGFC
45	anti-apoptosis	GO:006916	10.2	PIK3CA, RELA, SERPINB2, BRAF, VHL, BIRC5
46	response to ethanol	GO:045471	10.1	BCL2, S100A8, CDK1, MMP9, INSR, CCNE1
47	aging	GO:007568	10.1	VDR, VCAM1, P2RY2, JUN, AQP2, APOD
48	platelet activation	GO:030168	10.1	PIK3CB, PIK3CA, PIK3CG, SERPINE1, VEGFA, VEGFC
49	cellular response to hypoxia	GO:071456	9.6	SFRP1, VHL, VEGFA, MTOR, MDM2, ICAM1
50	positive regulation of MAPK cascade	GO:043410	9.2	KIT, KDR, CDH2, FLT1, FLT4, AR

Molecular functions related to endometrial carcinoma according to GeneDecks:

(show all 14)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:005515	18.4	SLPI, EP300, EPAS1, EPHA2, EPHB4, EPO
2	sequence-specific DNA binding transcription factor activity	GO:003700	12.2	HIF1A, ELF1, WT1, CREBBP, CREB1, SMAD4
3	ATP binding	GO:005524	12.2	PTK2, DAPK1, PLK1, PDGFRB, KSR1, EGFR
4	protein kinase binding	GO:019901	11.6	CCND1, HSPB1, TP53, PTEN, PTK2, SPRY2
5	identical protein binding	GO:042802	11.6	RELA, SFRP1, PCNA, VIM, RASSF1, HSP90AA1
6	protein homodimerization activity	GO:042803	11.5	ABCG2, NOS2, PLEK, SMAD4, SMAD3, PTGS2
7	enzyme binding	GO:019899	11.5	HYAL2, TGFB1, PRKCA, CSF3, SLPI, PGR
8	protein heterodimerization activity	GO:046982	11.2	TP53, EGFR, HIF1A, TOP2A, TGFB1, TGFB3
9	steroid hormone receptor activity	GO:003707	11.1	ESRRB, PPARG, NR1H2, NR1I2, PGR, ESRRA
10	receptor binding	GO:005102	11.0	PDGFRB, NOS2, CRAT, CTNND1, TNFSF10, DPP4
11	heparin binding	GO:008201	10.9	ANG, CCL2, CYR61, LTF, ABP1, HBEGF
12	transcription factor binding	GO:008134	10.8	BCL2, BCL3, JUN, CDKN2A, CD34, AR
13	growth factor activity	GO:008083	10.7	VEGFA, VEGFC, ARTN, FIGF, INHA, TYMP
14	transcription regulatory region DNA binding	GO:044212	10.4	CTNNB1, PPARG, SMAD3, SMAD4, WT1, HIF1A